Every question, in order.

The Department of Justice moved two narrow kinds of cannabis from Schedule I to Schedule III. The first is cannabis in an FDA-approved drug product. The second — the one that matters for an OMMA license holder — is cannabis sold under a state medical marijuana license.

Everything else stayed in Schedule I. Recreational. Unlicensed. Synthetic THC. Cannabis sold as food or supplements.

Three things came out of the order. A new federal registration pathway opened for state-licensed medical operators, with a 60-day window to file the easy way. The federal tax penalty under Section 280E stopped applying to state-licensed medical activity starting tax year 2026. And state-licensed medical activity now operates, federally, as a Schedule III substance instead of a Schedule I one.

Acting Attorney General Todd Blanche signed the order. The natural question is whether the word acting makes the order weaker. The answer is no.

An Acting AG holds the same legal authority as a confirmed one. The rescheduling power Congress gave to the office in 1970 sits with whoever holds the office at the moment of signing. Blanche held it. He used it.

The lawsuits being prepared against the order will probably mention the acting title in passing. None of them rest on it. The real legal fight is about the route the order used to make the change — not about who held the pen.

Four dates are floating around. Here they are, in order, with what each one actually means.

April 22, 2026 — the order was signed. Internal date. Doesn't do anything to anybody.

April 23, 2026 — the announcement. The day the news broke. The day the industry started moving. Doesn't carry legal weight on its own.

April 28, 2026 — published in the Federal Register. This is the day the order became law. If a date matters for federal-law purposes, it's this one.

January 1, 2026 — not a date the order took effect at all. It's the start of tax year 2026, which is the full year the Section 280E tax relief covers. People confuse the two and it's an easy mix-up to make.

Two dates carry weight going forward. April 28, when the order went live. And June 27, when the 60-day window to file for federal registration the easy way closes.

Final. Already law. Not a draft, not a proposal, not waiting on a comment period.

Most federal rules go through a process where the agency proposes a rule, takes public comment for months, considers what came in, and then issues a final version. That process didn't happen here. The order skipped it, using a different legal authority that lets the Attorney General issue a binding order directly.

That shortcut is part of why some groups are getting ready to challenge the order in court. The challenge isn't to whether the order is in force — it is — but to whether the shortcut was the right one to use. While that fight plays out, the order is the law.

Executive Order 14370 was the president's instruction to the agencies. Trump signed it on December 18, 2025. It told DOJ, HHS, Treasury, and FDA to move quickly on rescheduling cannabis in a way that lined up with U.S. treaty commitments.

The executive order itself didn't reschedule anything. Presidents don't reschedule drugs. Agencies do. The EO was the directive — get this done — and the April 23 order is the agencies delivering on it.

No. Congress didn't vote on this. The President didn't sign a bill. No new law was passed.

This surprises people, because changing the legal status of cannabis sounds like exactly the kind of thing Congress would have to do. It isn't. Congress already did that part — back in 1970, when it passed the Controlled Substances Act and gave the Attorney General the authority to move substances between schedules administratively. Every rescheduling that has ever happened has happened that way. Congress wrote the rules of the game; the agencies play it.

What is unusual here isn't the absence of Congress. It's which path inside the agency authority got used. The standard path involves a long scientific review and a public comment period. The path used here was a faster one tied to a treaty obligation. That choice is the part being challenged in court — not the underlying authority.

The official version is in the Federal Register, dated April 28, 2026. That's the version that controls if anything ever comes down to exactly what does it say.

The DEA Diversion Control Division also hosts a copy on its website, alongside the new regulations the order put in place. Treasury and the IRS have published their own separate notices on the tax side.

Three names. One event.

The Final Order is the legal action — the Attorney General signing the paper that moves cannabis between schedules. That's the move itself.

The Final Rule is the package of new regulations that come along with the move. A new registration pathway. New paperwork requirements. Updates to existing rules so they fit the new schedule. The order makes the change; the rule makes the change work.

The Federal Register publication is the official document that contains both, plus the agency's written explanation of why it did what it did. It's the version everyone cites.

In conversation, people use these terms interchangeably and it's usually fine. If you ever need to point to the official one, it's the Federal Register publication.

Most federal rules take a long time to change. The agency has to study the substance, ask experts, take public comment, weigh it all, and write a careful new rule. That whole process for cannabis got started back in 2024 — and it stalled out. The judge running it stepped aside, the proceeding sat dormant, and by early 2026 nobody was moving it forward.

So the government used a different path. A long time ago, the United States signed a worldwide agreement with most other countries about how drugs get categorized. There's a provision in U.S. law that says: if a drug needs to move so U.S. law matches what that agreement allows, the Attorney General can issue a direct order. No long study. No comment period.

That's the path they used. The reasoning: medical cannabis fits where the agreement allows medical drugs to sit. Schedule III is that spot. Move it there.

It's legal authority, real and on the books. But it's a path that was mainly built for adding restrictions to match the treaty, not for removing them. The argument that the path wasn't built for changes this large is what's going to court.

Two narrow things.

First, cannabis inside an FDA-approved prescription drug. The category is small today — Epidiolex is the main product in it — but it's the legal pathway for any future cannabis-derived drug that gets through FDA approval.

Second, and this is the one that matters for an OMMA license holder: cannabis sold under a state medical marijuana license. That covers the plant material, the extracts, the edibles, the topicals — anything moving through a state-licensed medical supply chain to a qualifying patient.

On the federal paperwork, drug codes 7362 (marijuana), 7353 (marijuana extract), and 7386 (naturally-derived Δ9-THC) apply depending on what you handle. Those are the numbers that go on DEA registration filings.

Everything the order didn't name. The two categories that moved are narrow — everything outside them stays where it was.

That includes recreational/adult-use cannabis. It includes unlicensed cannabis, even where state law allows certain unlicensed activity. It includes synthetic THC products. It includes cannabis sold as food, as a dietary supplement, or as an unapproved drug (the FDA piece — separate from how the DEA schedules it). And it includes extracts that don't fall under either the FDA-approved-drug category or a state medical license.

The leftovers are bigger than the categories that moved. That's the part the news coverage tends to miss.

Three ways to read the line.

By activity: cultivation, processing, distribution, and dispensing performed under an OMMA license.

By product: flower, extracts, edibles, topicals — anything produced and moved inside the licensed medical supply chain.

By transaction: transfers between OMMA-licensed entities, and sales to qualifying medical patients.

The important thing to understand: the schedule status follows the license, not the plant. The same chemical compound is Schedule III when it's moving through a state-licensed medical channel, and Schedule I when it's moving through an unlicensed or recreational channel. The molecule doesn't change. The legal status does.

It's the category for cannabis-derived prescription medicines that have gone through the FDA approval process.

Today there's essentially one product in it: Epidiolex, a cannabidiol oral solution prescribed for certain rare pediatric epilepsy syndromes. A handful of other cannabis-derived drugs are working their way through FDA — some closer than others. Anything that gets approved drops into this category automatically.

It's a small category right now. Long-term, it's the legal lane for any pharmaceutical-grade cannabis product.

No. Recreational cannabis is still in Schedule I. The order didn't address it.

There is a separate proceeding underway that might eventually move recreational too — the DEA hearing scheduled for June 29, 2026 is the start of it. But that's a slower process, and any rule that comes out of it won't take effect in 2026. Late 2027 is the optimistic timeline. 2028 is more realistic.

For now, recreational is where it was.

Still Schedule I from the DEA's side. And separately, still a problem from the FDA's side.

The FDA treats cannabis-containing products that haven't gone through drug approval as either unapproved drugs (if anyone is making health claims about them) or as products that don't fit the food and supplement categories. The rescheduling order didn't change any of that.

For an operator producing cannabis-infused food or beverages under an OMMA license, the situation is layered. The product is Schedule III for federal controlled-substance purposes — because it's state-licensed medical. But it can still face FDA enforcement on a completely separate track if it's marketed in a way that triggers the FDA's drug or supplement rules. Two regulators, two frameworks, one product.

The order doesn't say. The federal text talks about "marijuana subject to a state medical marijuana license," and OMMA patient cards are state-issued authorization under the medical marijuana program — but a patient card isn't structured the same as a commercial license.

The honest answer is that home grow under a patient card is in a gray area. DEA hasn't issued specific guidance on it. The conservative read is that the order was written with commercial licensees in mind and patient home grow wasn't the target either way.

For a commercial operator, this question usually comes up because patients ask. The best framing for the patient: nothing about your right to grow at home under your OMMA card changed because of the federal order. State law governs that, and state law didn't move.

Same question, same gray area as patient home grow. OMMA's caregiver designation runs through the patient-card system rather than through a separate caregiver license — which is what makes the federal question fuzzy.

If the federal text "marijuana subject to a state medical marijuana license" is read narrowly as commercial licensing only, caregiver cultivation sits outside it. If read broadly as any state authorization, it sits inside. DEA hasn't picked.

Like the home-grow question: caregivers operating under OMMA designations didn't lose any state-law authority. The federal change is silent on them.

Section 280E is a federal tax rule that says any business trafficking in a Schedule I or II controlled substance can't take ordinary business deductions.

You can still deduct cost of goods — the actual cost of the product you sold. That's a constitutional floor and it never moved. But everything else — rent, payroll, utilities, marketing, professional fees, depreciation — none of it was deductible under federal law as long as cannabis was Schedule I.

The practical effect: cannabis operators have been paying federal income tax on something close to gross profit, not net income. For a lot of operators, effective federal tax rates ran above 70 percent on book income. That's the rule the April 28 rescheduling ends for state-licensed medical operators.

The legal trigger is the rescheduling taking effect on April 28, 2026. The order is explicit: holders of state medical marijuana licenses are no longer subject to the 280E disallowance as a result of the rule.

For the return you file, the IRS and Treasury have said the relief applies to the full 2026 tax year. Tax year 2026 is the first year you can take operating expense deductions under federal law.

Wrong as a legal date. Understandable as shorthand for the tax year.

The rescheduling order took effect April 28, 2026 — not January 1. But the IRS and Treasury have said the tax relief applies to the full 2026 tax year, which started January 1. So in terms of what it means for your return, the practical answer is the full year counts.

Anyone telling you the law changed January 1 is repeating a misreading. The correct statement is: the law changed April 28, and the IRS is treating the full 2026 tax year as the first year of relief.

Not automatic in the sense that deductions appear on your return without action. You have to claim them.

The legal basis exists now — the rescheduling is the trigger, and it's already done. But deductions don't happen unless you put them on the return. The open question right now is exactly how to position those deductions methodologically, since the IRS hasn't issued final guidance yet on the mechanics. That's a conversation to have with your CPA before the return is filed, not after.

No. These are two separate things.

The DEA registration is your federal operating credential under the new Schedule III framework. The 280E relief is a tax consequence of the rescheduling itself. The order is explicit: the 280E disallowance ends because of the rescheduling, not because you registered. You could have 280E relief without a federal registration. You could have a federal registration without it affecting 280E. They run on separate tracks.

Don't let anyone conflate the two.

Speculative. Worth watching, but don't plan around it.

The order encouraged Treasury to consider giving relief for prior years when an operator was running under a state medical license. That's a suggestion, not a mandate. Treasury and IRS said on April 23 they plan to issue guidance — but as of mid-May 2026, nothing is formalized.

Plan your 2026 return assuming that year is the first year of relief. If retroactive relief eventually comes through for 2022, 2023, or 2024, that's upside. Build toward that position now if your CPA recommends it, but don't file amended returns yet.

Don't file amended returns for prior years yet. The legal basis for a retroactive 280E deduction position doesn't exist until IRS issues guidance on it. Filing now is getting ahead of the law.

Protective refund claims are a different question. A protective claim stakes out your position before a refund opportunity expires under the statute of limitations, without requiring you to fight it today. For tax years 2022, 2023, and 2024 specifically — where refund windows could close before guidance arrives — it's worth a conversation with your CPA about whether a protective claim makes sense.

The line is: wait on amended returns, ask your CPA now about protective claims.

Treasury and IRS announced on April 23, 2026 that guidance is coming. As of mid-May 2026, nothing has been issued.

When it arrives, expect it to cover: confirmation that 280E doesn't apply to state-licensed medical operators for 2026 and forward, the transition period (April 28 treatment), and possibly a position on retroactive relief for prior years.

This page will be updated when guidance drops. Check the update date.

Less pressure to maximize COGS.

Under 280E, operators worked hard to push as many costs as possible into cost of goods sold — because COGS was the only bucket that reduced taxable income. Some of that involved aggressive interpretations of the Section 263A inventory capitalization rules.

With operating expenses now deductible on the federal return, those costs come out either way. The incentive to push everything into COGS evaporates. Expect downward pressure on aggressive Section 263A positions in 2026, both in how operators file and possibly in how the IRS approaches it.

The OMMA excise and sales taxes on medical cannabis don't change. Those are state taxes and the federal rescheduling doesn't touch them.

For Oklahoma income tax: Oklahoma conforms to the federal Internal Revenue Code. The state follows the federal adjusted gross income calculation. So the 280E change that flows through on your federal return generally flows through to your Oklahoma income tax return as well.

Confirm the specifics with your CPA — state conformity questions are fact-specific — but the directional answer is that the federal 280E relief carries through to Oklahoma.

Substantial. Industry projections put effective rates for qualifying medical operators at roughly 20 to 30 percent post-relief, down from the 70-percent-plus range most were paying under 280E.

What you actually land at depends on how expense-intensive your operation is, how COGS is treated, and your entity structure. But the directional answer is a significant improvement in after-tax cash flow starting with the 2026 return.

Low risk for the 2026 return, if the position is grounded in the order itself and taken in good faith.

The federal penalty rules require "substantial authority" or "reasonable basis" for a return position to avoid accuracy-related penalties. The rescheduling order is a final agency action that explicitly ends 280E's application to state-licensed medical operators. A deduction position resting on that order, applied in a reasonable way, is on solid enough ground for the 2026 return.

The risk goes up sharply if you file amended prior-year returns claiming retroactive relief before the IRS says that's allowed. That's the conservative line to hold.

"Trafficking" in Section 280E just means being in the business of buying or selling the substance. Courts set a low bar — it's not about volume or intent, just whether you're in that business. State legality doesn't matter.

Before April 28, 2026: every cannabis business was trafficking in a Schedule I substance under federal law. Didn't matter if you had an OMMA license. Federal law saw one thing.

After April 28, 2026: state-licensed medical operators are trafficking in a Schedule III substance. Section 280E doesn't cover Schedule III. So the deductions open up.

The word trafficking didn't change. The schedule did. That's the whole mechanism.

A new category of federal registration, created specifically for operators holding a state medical marijuana license.

Before April 28, 2026, there was no federal registration pathway for a cannabis business. The DEA didn't have a box for you. The April 23 order created one — Section 1301.13(k) — and the DEA opened the application portal on April 29.

Your OMMA license is the foundation. The application uses it as conclusive proof that your state has authorized your activity. The DEA is then required to grant the federal registration unless there's a specific public-interest reason to refuse.

The registration is what gives you federal-law cover to operate as a Schedule III business. Everything the rescheduling opens up — banking access, federal commerce relationships, federal frameworks as they develop — flows through it.

Any entity holding an OMMA license that plans to keep manufacturing, distributing, or dispensing under federal Schedule III.

That means dispensaries, processors, growers, and transporters. Vertically integrated operations — where one entity holds multiple license types — file a separate registration for each activity type. And a separate application is required for each physical location.

If you hold an OMMA license and intend to continue operating, you need to register.

Several categories are outside the lane.

Recreational-only operators — no rec program in Oklahoma so this one is moot here, but worth knowing nationally. Hemp businesses operate under a separate federal framework entirely. Operators handling synthetically derived THC. Operators without a current, active OMMA license. And anyone whose OMMA license has been suspended or revoked — if the state license is gone, there's nothing to anchor the federal registration to.

The pathway is specifically for active state-licensed medical operators. If the OMMA license isn't current, the pathway isn't open.

June 27, 2026. That's 60 days from the Federal Register publication date of April 28.

For practical purposes, treat June 26 as your deadline. That's the last business day before the cutoff. Filing on June 27 is technically within the window, but leave yourself a business day of buffer — the portal has already seen heavy traffic.

Some early coverage cited June 22. That date was wrong. The publication date was April 28; the correct deadline is June 27.

Two things you get inside the window that disappear after June 27.

First, a processing target. The DEA Administrator must make every effort to decide your application within six months. File by June 27 and you have that commitment. File later and there's no timeline at all — standard DEA registration processing has historically run anywhere from a few months to well over a year.

Second, and more important: the right to keep operating under your OMMA license while your federal application is pending. File inside the window and you're protected. The federal rule explicitly authorizes continued manufacture, distribution, and dispensing under your state license during the review. File outside the window and that protection doesn't apply. During the review period, you'd be handling a Schedule III substance without federal authorization.

Same application. Same pathway. Materially different situation depending on which side of June 27 you're on.

Three layers of better.

The window. Filing by June 27 gets you a six-month processing target and the right to keep operating under your OMMA license while the federal application is reviewed. Those two protections go away after the window closes.

What the registration itself does. Once registered, you have federal-law authorization to handle a Schedule III substance. The DEA must grant it unless there's a specific public-interest problem with your application. You use your existing OMMA-compliant SOPs, security, and recordkeeping to satisfy most federal requirements — you're not double-regulated, you're regulated once with federal recognition layered on.

What it opens downstream. Banking and payment relationships that require Schedule III compliance treat DEA registration as the entry ticket. Any commerce between federally registered businesses — research arrangements, supply-chain transactions, whatever federal frameworks emerge from here — requires registration as the baseline. Every federal benefit of Schedule III flows through this registration.

One thing registration doesn't control: 280E relief. That flows from the rescheduling itself, not from registration. Don't mix the two up.

Nobody comes to shut you down. The federal government has been clear that the registration process isn't intended as an enforcement net for state-licensed operators. Your OMMA license still works. Patients still come. Day to day, things look the same.

But quietly, you fall behind.

Banking and payment relationships that open up for registered Schedule III operators don't open for you. Any chain of commerce that requires registrant-to-registrant documentation is closed off. Federal frameworks built on registration as the baseline — whatever Congress, Treasury, or DEA build next — won't include you. And the operators next to you who did register are moving into territory you're locked out of.

And if you change your mind later? You can still apply. But the window closed June 27, so you lose the six-month processing target and the right to keep operating while you wait for an answer.

The honest summary: not registering is survivable. It's also, under the new regime, the strictly worse position. The cost is paid in slow compounding losses, not in a single dramatic event.

Technically optional. Practically, it's the wrong frame.

The federal rule doesn't force you to register. Nobody will fine you on June 28 for not having filed. But every federal benefit the rescheduling created — banking access, federal operating authorization, federal commerce relationships, whatever frameworks develop from here — requires registration. Calling it "optional" is technically accurate in the same way it's technically optional to show up for your OMMA renewal.

For any medical operator planning to be in business in 2027 and beyond, the meaningful choice isn't file or don't. It's file now with the window open, or file later without the protections.

Yes, but the bar is high and the presumption runs in your favor.

The rule says the Administrator must grant the registration unless doing so would be inconsistent with the public interest or with U.S. treaty obligations. That's a must-grant standard with narrow exceptions — not discretionary approval.

The public-interest factors the DEA looks at are things like: prior DEA history, compliance record, diversion controls, criminal history of principals. For an OMMA-licensed dispensary or processor that's been in good standing, those factors point toward approval.

Refusals will happen, but they'll be based on specific concerns about a specific applicant — not blanket discretion to turn away state-licensed operators.

It means the default answer is yes, and the DEA has to have a real reason to say no.

Most federal approvals work the other way: the applicant has to prove they deserve it. This one flips that. The rule puts the burden on the agency. If the DEA wants to deny your application, it has to point to something specific — a compliance problem, a criminal history, a diversion risk — and explain why that specific thing makes approval inconsistent with the public interest.

For an operator that's been running clean under an OMMA license, "inconsistent with the public interest" is a difficult standard for the DEA to meet. That's by design.

Two different forms for two different roles.

Form 224 is for dispensers — the retail side, selling to qualifying patients. If you hold an OMMA dispensary license, this is your form.

Form 225 is for manufacturers and distributors. That covers growers, processors, and transporters.

If your operation is vertically integrated — say you grow, process, and dispense — you file both. One 225 for the upstream activities, one 224 for the dispensing side. Same legal entity, two separate registrations.

Both location and activity type. Each physical address gets its own application. Each activity type (grower, processor, transporter, dispenser) gets its own registration.

Same legal entity, multiple registrations. A single OMMA licensee with a grow site, a processing facility, and three dispensary locations files five separate applications — one for the grow, one for processing, three for the dispensaries.

The registration scope at each location can't go beyond what the OMMA license at that location allows.

Inside the window: the DEA must make every effort to decide within six months. Applications filed by June 27 are targeting decisions by approximately late October or early November 2026.

Outside the window: no timeline. Standard DEA processing has historically ranged from a few months to well over a year. There's no commitment, no queue priority, and no during-pendency operating protection while you wait.

Yes — if you filed inside the window.

The rule explicitly authorizes continued operation under your OMMA license during the review of your federal application, for operators who filed by June 27. You're covered. Keep running.

If you file after the window closes, that protection doesn't apply. Operating during the review period of a late-filed application means handling Schedule III cannabis without a federal registration — which is federally unauthorized handling of a controlled substance. The legal gap is real even if enforcement is unlikely.

The federal registration automatically suspends the moment the state license is suspended, revoked, or expires. There's no grace period. The federal authorization goes away when the state authorization goes away.

Reinstatement of the federal registration follows reinstatement of the OMMA license, but it's not automatic — there's a notification process to go through.

The practical implication: your OMMA renewal calendar needs to be on the radar before your federal renewal calendar. State first, always. A lapsed OMMA license is the fastest way to lose the federal registration.

Depends on your activity type.

Dispensaries renew every three years. Manufacturers and distributors renew annually. Renewal cycles run from the date your registration is granted, not the date you applied.

Factor this into your compliance calendar alongside the OMMA renewal schedule. The two run on different timelines and both need to stay current.

Application fee: $794 per location, paid at filing. Covers every activity type at that location.

Renewal fees: manufacturers pay approximately $3,699 per year; distributors approximately $1,850 per year; dispensaries approximately $888 per three-year cycle — roughly $296 per year equivalent.

Payment at filing is currently processed through PayPal. Additional payment methods are reportedly being added. Confirm current fee amounts on the DEA Diversion Control fee schedule before filing — the numbers are subject to periodic adjustment and these figures reflect the schedule as of mid-May 2026.

The DEA Diversion Control Division portal at deadiversion.usdoj.gov. Standard browser, no special software.

If your entity doesn't already have a DEA registrant account — most cannabis operators won't — you create one before you can start the application. Supporting documents upload as PDFs.

The portal opened April 29, 2026. It has already seen heavy traffic. Don't leave the filing for the last day before June 27.

More than you'd expect. Treat the prep phase as a one-to-two-week project, not a same-day task.

At minimum, have ready before you open the portal:

• Entity legal name and any DBAs
• EIN
• Business address for each location you're filing
• Organization type and ownership structure, including any changes in ownership history
• Current OMMA license documentation — license number, expiration date, clean PDF of the official license
• List of suppliers you source from, with their DEA registration numbers if they have them (most won't yet)
• Names and biographical detail for everyone who will have access to controlled substances at the location — including Social Security numbers and criminal history
• Your SOPs: cultivation, processing, security, inventory, recordkeeping, disposal — whatever applies to your license type
• Payment information for the $794 application fee

The application has seven sections.

1. Personal/Business Information. Entity name, EIN, address, organization type, ownership history, prior DEA registrations.

2. Activity. What substances you handle. State-licensed medical marijuana is drug codes 7362 (marijuana), 7353 (marijuana extract), and 7386 (naturally-derived Δ9-THC), depending on what you handle. There's also an explicit yes/no question about whether you handle recreational marijuana — answer honestly.

3. State License(s). Your OMMA license number and expiration date.

4. Liability Questions. Five questions covering criminal history, federal licensure history, professional licensure history, and — the one that matters most — whether anyone in your ownership or operation has previously handled a controlled substance without a DEA registration authorizing it. Most established operators answer yes. Read the disclosure section of this FAQ before you answer this one.

5. Compliance Information. Supplier list with DEA numbers, your SOPs by activity type, and personnel disclosures for everyone with access to controlled substances.

6. Payment. The $794 application fee.

7. Submission. Final review and certification that everything you've said is accurate, under penalty of federal law.

A current, unexpired copy of your OMMA license. Most OMMA licenses are issued digitally; a clean PDF of the official license document is what the portal accepts.

The license must be in the name of the entity that is filing. If the license is held under a different legal name than the one applying — because of an acquisition, a restructuring, or a name change — sort that out before you file. The DEA uses the state license as conclusive evidence of authorization. If the names don't match, that evidence doesn't hold.

Section 5 asks you to identify your medical marijuana suppliers by name and, where they have one, their DEA registration number.

Here's the practical problem: most suppliers in the early window won't have federal registrations yet, because everyone is filing at the same time. Where a supplier doesn't have a DEA number yet, use their OMMA license information instead.

If your supplier list changes after you've been approved, you have ongoing update obligations. It's not a one-time disclosure.

The application asks whether you have SOPs for each activity you conduct — cultivation, manufacturing, packaging and labeling, dispensing, inventory, recordkeeping, security, disposal, and personnel access controls.

The answer for most OMMA operators is yes. OMMA compliance has required documented procedures in most of these areas for years.

The important distinction: you're identifying that SOPs exist, not uploading the full text. Your SOPs need to be on the shelf and available for inspection — not attached to the application.

State-law SOPs are accepted where they meet federal minimums. Most mature OMMA-compliant SOP packages do. Where they don't — primarily in areas where state law is silent and federal law has specific requirements — a federal addendum may be needed. That's a relatively narrow gap for most operators.

For every person who will have access to controlled substances at the registered location: full legal name, biographical detail, Social Security number, any individually-held DEA registration numbers, and criminal history.

The "who" is broader than just your security staff or your compliance officer. It covers anyone in the chain of custody at the location — which in a dispensary setting, for example, includes anyone who handles product. In a grow or processing facility, it includes anyone with access to the plant area.

This is one of the sections that takes time to assemble. Start the personnel roster early in the prep phase.

Criminal history is self-disclosed in the application for each person you list in the personnel section. You report it; the DEA then conducts its own background investigation as part of the review.

OMMA background-check documentation — whatever you collected when those employees were hired — should be retained on-site and available for inspection, but it generally doesn't get uploaded with the federal application.

Be accurate in what you self-disclose. The DEA will verify it. Discrepancies between what you report and what the investigation finds are a more serious problem than the underlying history itself.

The $794 application fee is currently paid through PayPal at the time of submission. Additional payment methods are reportedly being added to the portal, but PayPal is what's available now.

Renewal fees — when they come due — use existing DEA fee-payment infrastructure, which supports ACH and check in addition to online payment.

The $794 is per location. An operator filing for three dispensary locations files three applications and pays three fees.

Yes, through the DEA's standard modification process. But don't treat post-submission amendment as a substitute for a clean initial filing.

Minor corrections go through the registrant portal. Material changes — ownership structure, activity scope, location address — require a formal modification and restart certain parts of the review. An amendment is not a do-over; it adds process.

Get it right the first time. The prep work in the two weeks before you file is how you do that.

Separate filings for each state, each location, each activity type. There's no consolidated multi-state registration. An operator in Oklahoma and Florida files in both states separately, with separate state-specific license documentation, separate personnel disclosures where personnel differ, and separate fees per location.

This is mostly a question for operators already thinking about expansion. If you're Oklahoma-only right now, the answer is simple: one state, one set of filings.

Several. One legal entity, multiple registrations.

Each activity type — grower, processor, distributor, dispenser — requires its own registration, even under the same entity. Each physical location requires its own application.

A fully vertical operation with a single grow site, a single processing and distribution facility, and three dispensary locations files five registrations: one for the grow (Form 225), one for processing/distribution (Form 225), and three dispensary registrations (Form 224, one per location). Five applications, five fees.

The scope of each registration is bounded by the OMMA license at that location. A Form 225 filed on a grower license can't be used to authorize dispensing.

Early filers — submitted by June 27, 2026: six-month processing target. Plan for decisions in the late October to early November 2026 range, with some variation depending on how complex your application is.

During that period, if you filed inside the window, you're authorized to keep operating under your OMMA license. The timeline is less operationally critical for you than it is for a late filer, because you have cover while you wait.

Late filers — submitted after June 27: no timeline commitment. Historical DEA processing has ranged from a few months to well over a year. No during-pendency operating protection. The wait is both indefinite and legally exposed.

Honestly. Yes is the right answer for most established operators.

Here's the reasoning. Before April 28, 2026, every state-licensed cannabis activity in the United States was, federally, handling of a Schedule I substance without a DEA registration. That's what the law said and that's what every OMMA-licensed operator was doing, regardless of how clean the state-side compliance was. The federal text didn't distinguish between an operator running clean under state license and an operator running an illegal grow.

So if you've been operating in Oklahoma under an OMMA license for any meaningful period before April 28, the truthful answer to the question is yes.

False or incomplete answers are federal crimes under 18 U.S.C. § 1001 and 21 U.S.C. § 843. The DEA verifies what you disclose. Getting caught lying is much worse than the underlying history. DOJ has signaled it does not intend to use this disclosure as an enforcement tool against state-licensed operators — that's why the question is survivable. It's not why the question can be skipped or shaded.

This is the question on the application most worth running past counsel before you submit. The yes-answer narrative matters.

In a narrow technical sense, yes. The application puts on the federal record activity that was, before April 28, federally unauthorized handling of a controlled substance. That record exists now in a way it didn't before.

The exposure is heavily mitigated by three things working in operators' favor. First, DOJ has explicitly said it does not intend to use this process to enforce against state-licensed operators. Second, the rescheduling itself prospectively legalizes the activity going forward — the conduct being disclosed is now permissible activity for a state-licensed medical operator. Third, the rule's structural presumption in favor of granting registration means the disclosure is the path to federal cover, not a trap.

The exposure is not zero. Operators with unusual fact patterns — prior federal investigations, criminal records of principals, activity that went beyond what state license authorized — face higher residual risk and should engage counsel before filing. For the typical operator running clean under OMMA, the disclosure carries the protection of the broader regulatory design around it.

Yes — multiple signals, all pointing the same direction.

The rule preamble itself indicates DOJ does not intend the registration process as an enforcement tool against state-licensed activity. Acting AG Blanche's statements at the time of signing reinforced the same point. And the structural design of Section 1301.13(k) — cooperative federalism with the state, automatic suspension tied to the state license, the presumption of granting registration — is consistent with a posture of integration rather than enforcement.

None of these signals are legally binding. They're policy, not law. A future administration could take a different posture toward the same disclosed information. The signals are reasons to file with confidence; they aren't guarantees.

No formal safe harbors. No non-prosecution agreements. The protections for state-licensed operators come from two places: the rescheduling itself, and DOJ's enforcement priorities.

The rescheduling is structural and durable. It changed federal law and the federal characterization of state-licensed medical activity. That protection isn't going anywhere short of the order being overturned in court or repealed by Congress.

Enforcement priorities are discretionary. They can shift with an administration change. Today's posture is favorable to state-licensed operators; the same posture is not guaranteed forward.

Operators who want belt-and-suspenders protection beyond the structural protections sometimes seek individualized opinions of counsel, or in unusual cases, pre-filing consultation with DOJ. Those are case-by-case calls for operators with specific concerns, not standard practice.

Limited registrant information shows up in the DEA's public registrant database: name, address, DEA number, registration type, activity, expiration date. That's the standard transparency for any DEA registrant.

The substantive application content — financial information, personnel disclosures, criminal histories, ownership detail, supplier lists — is not generally public. It sits inside the agency.

That said, it isn't locked away. Information in the application can be reached through specific legal processes: FOIA requests (subject to redactions), subpoenas in litigation, regulatory inquiries, congressional oversight. The application should be treated as a document that may eventually be examined by parties beyond DEA review staff — not as a confidential filing.

Severe. Three categories of consequence.

Criminal. False statements on the application are federal crimes under 18 U.S.C. § 1001 and 21 U.S.C. § 843. Each carries potential imprisonment and substantial fines. The certification you sign in Section 7 puts the consequences on the record.

Civil. Immediate registration denial or revocation. If a false statement is discovered after the registration is granted, the registration is revocable and the path back to good standing is long and uncertain.

Reputational. Revocation orders are public record. The DEA publishes them. For an OMMA-licensed operator depending on banking relationships, vendor relationships, and patient trust, a public DEA revocation is a structural problem that extends well beyond the federal registration itself.

The combination of severity and the verifiability of the application makes shading the answers a worse decision than honest disclosure with counsel-managed framing. The disclosure questions can be survived. False answers can't.

Federal minimums for Schedule III substances cover four categories: receipts, dispositions, inventory, and any losses or thefts.

The good news for OMMA-licensed operators: the state already requires most of this. Your seed-to-sale tracking system — Metrc, BioTrack, or equivalent — captures the transaction-level detail that satisfies federal recordkeeping for receipts and dispositions. The federal rule accepts state-required records to the maximum extent the treaty and federal statute allow.

For most operators with mature state-side tracking, the incremental federal recordkeeping burden is minimal. The records you're already keeping generally work.

Every two years, a comprehensive physical count of all controlled substances on hand at the registered location. Not an estimate — an actual count.

The inventory needs to document each substance, its form, quantity, and location. Records must be kept for at least two years and be ready for DEA inspection.

For most dispensaries and processors running Metrc, your system-of-record inventory should track closely to the physical count. The biennial inventory is largely a verification exercise against what your state tracking system already shows.

State-law security requirements substitute for federal ones where the state regime is robust enough. OMMA's security requirements — vault storage, alarmed perimeters, camera coverage, restricted access, transport security — meet or exceed federal Schedule III minimums in most respects.

For standard dispensary, processing, and cultivation operations, your existing OMMA-compliant security setup generally satisfies the federal standard. You're not building a second security layer on top of what you already have.

The exception is activity where state law is silent — primarily import/export operations and certain specific manufacturing protocols. Those areas run against federal minimums directly. For the typical OMMA medical operator, import/export won't apply.

The federal warning required by 21 U.S.C. § 825(c) for controlled substances. The exact language is set by statute and DEA implementing regulations — it's not something you write yourself.

This is the one packaging requirement that gets added on top of your existing OMMA-compliant labels. Everything else on your label stays as-is under state law. The federal warning goes on in addition.

Get the exact language from the DEA Diversion Control Division site or through your counsel before you update your packaging. The wording is specific.

State law covers almost everything. OMMA labeling and packaging requirements remain in full effect: cannabinoid content, dosage information, testing results, dispensary and patient identification, child-resistant packaging where required.

The federal registration adds one thing: the Section 825(c) warning label described above.

The implementing regulations explicitly exempt registered operators from the federal Part 1302 labeling and packaging requirements when they're complying with state law and adding the federal warning. You're regulated once, under OMMA rules, with the federal warning label added on.

State-law disposal protocols are accepted. OMMA requires documented destruction of unused, expired, or unsalable cannabis — most operators have an established disposal procedure already.

Metrc captures disposal events. Those records satisfy the federal documentation requirement.

If OMMA's disposal requirements and procedures are already in your SOPs and tracked in Metrc, your federal disposal obligations are covered by what you're already doing.

DEA inspectors can enter your registered premises during normal business hours for compliance inspections. For most routine inspections, you'll get advance notice. Unannounced inspections are reserved for specific cause — a complaint, a diversion flag, or something that comes up in a review.

For manufacturers specifically, there's an additional element during the period of the nominal-price purchase-and-resale mechanism (see the manufacturers question below). DEA has access to storage facilities during that process.

For dispensaries: routine federal inspections will be relatively infrequent in the early years. DEA has finite capacity and a large new registration population to manage. Expect state inspections to remain more frequent than federal ones for the foreseeable future.

This one affects growers and manufacturers only — not distributors or dispensaries.

Here's the background. A 1961 international treaty the U.S. signed — the Single Convention on Narcotic Drugs — requires the federal government to maintain a monopoly on wholesale trade in narcotic crops. For cannabis, that would normally mean the government actually takes possession of the crop at some point in the supply chain.

Rather than physically seizing state-licensed cannabis, the DEA executes a paper transaction: it "purchases" the manufacturer's crop at a nominal price, then immediately "sells" it back to the manufacturer at that same price plus a small administrative fee. The crop never physically moves. The federal monopoly requirement is satisfied on paper. The April 23 order also frames state-licensed marijuana as expressly exempt from parts of the treaty's monopoly requirement, so the paper transaction is one piece of the treaty-compliance posture, not the whole picture.

It's a regulatory technicality. Understand it's coming and what it means.

Permits are required for any cross-border movement of state-licensed medical cannabis. Required even if everything else about the activity is legal under state and federal Schedule III rules.

For the vast majority of OMMA-licensed operators, this will never come up. The permits matter most for FDA-approved drug-product manufacturers — Epidiolex-type products moving in pharmaceutical supply chains — and for whatever future interstate commerce framework might eventually emerge.

If import or export isn't part of your current operation, this requirement is theoretical for now.

Federal reporting requirements are satisfied by state seed-to-sale tracking where the state system captures the required data points. For OMMA operators on Metrc, that's most of it.

What DEA needs to see: acquisitions, dispositions, inventory levels, and any losses or thefts. Metrc captures all of those as part of OMMA compliance. The federal layer is satisfied by the state layer for the most part.

Operators in states with weaker tracking face more incremental federal burden. Oklahoma's Metrc requirement is one of the reasons OMMA-licensed operators generally have an easier post-registration compliance transition than operators in states that don't mandate seed-to-sale tracking.

Pre-registration: an initial inspection of the registered location is common, particularly for manufacturers and distributors. DEA will want eyes on the physical facility before granting the registration in many cases.

Post-registration: routine compliance inspections vary by activity type. Manufacturers see more frequent attention than dispensaries. For most OMMA-licensed dispensaries, expect federal inspection frequency to be relatively low in the early years — DEA is managing a large new registration population and has limited capacity.

Complaint-driven and cause-based inspections are unannounced and operate on a different track. If a specific concern is flagged — a diversion incident, a compliance complaint — that inspection doesn't wait for the routine schedule.

DEA registrations are tied to the specific entity that holds them. They don't transfer automatically.

In an asset acquisition — where the buyer is purchasing the business assets rather than the entity itself — the buyer needs to file its own registration. There's a gap between closing and the new registration being granted; plan for it.

In a stock acquisition, where the legal entity itself is purchased and continues operating unchanged, a modification to the existing registration may cover the ownership change rather than requiring a fresh application. That's a more favorable outcome but still requires DEA notification and processing.

M&A planning needs to include DEA registration treatment as a closing condition. An operator without a plan for the federal registration gap is creating a period where its operations lack federal-law cover.

The federal registration suspends automatically. Immediately — there's no grace period where the federal registration stays active after the state license goes away.

Reinstatement of the federal registration follows reinstatement of the OMMA license, but it's not automatic. A notification process with DEA is required. The federal registration doesn't simply reactivate when the state license is restored; you have to notify DEA and complete the reinstatement process.

The practical priority: maintaining OMMA compliance is the single highest-priority federal compliance obligation, because losing the state license means losing the federal registration at the same moment.

Yes, but incrementally — and the access is conditioned on being registered.

Several institutions have signaled they'll treat DEA registration as the threshold for opening cannabis-banking relationships under the new regime. A registered medical operator is a meaningfully different banking customer than an unregistered one, even if both hold the same OMMA license.

Expect a tiered market over the next 12 to 18 months. Registered medical-only operators see real improvement in account access, payment relationships, and depository services. Mixed operators — medical plus recreational — face slower progress because the recreational exposure remains Schedule I. Recreational-only operators see little change in 2026.

For an OMMA-licensed medical operator, the path to better banking runs through the DEA registration.

Yes. The rescheduling solved part of the banking problem — for state-licensed medical operators. SAFE Banking would solve the rest of it, particularly for recreational and rec-exposed operators.

The political case for SAFE Banking is now more complicated. Some legislators will argue the rescheduling reduces the urgency. Others will argue that registered medical operators now have a clearer story to tell about why SAFE is still needed for the parts of the industry the rescheduling didn't reach.

For OMMA-licensed medical operators specifically, SAFE's incremental value is smaller than it was before April 28. The rescheduling did the heavy lifting. SAFE would be additive rather than transformative.

On a similar trajectory to banking, with a delay.

Major processors — Visa, Mastercard, Stripe, Square — haven't announced blanket policy changes. But specialized cannabis-payments providers are repositioning around DEA-registered medical as a distinct category they'll work with on better terms than general cannabis-sector activity.

ACH and depository changes through the banking channel will likely lead card-network changes by months. So depository access improves first; merchant card acceptance improves later.

For OMMA-licensed dispensaries operating mostly on cash and limited debit programs, the improvement is real but will be gradual through 2026 and into 2027.

Materially positive across all three dimensions for medical-positioned operators.

Valuation. 280E reversal flows directly to free cash flow, which is the input that drives most cannabis-sector valuations. Multiples should expand as the sector normalizes toward standard consumer or health-product comparables, rather than carrying the depressed cannabis-discount that 280E created.

Debt capacity. Improved free cash flow improves debt-service coverage, which is what lenders look at. Operators who couldn't carry traditional debt under 280E can now carry materially more.

M&A activity. Expect acceleration. Balance sheets are unlocking, acquirer financing is improving, and the regulatory environment is moving toward something resembling a normal industry rather than a quasi-illegal one. Strategic and financial buyers that had been on the sidelines are reentering.

For Oklahoma operators specifically, this matters most for owners contemplating an exit or a recapitalization. The window for transacting at improved multiples is opening.

Improving for medical-focused operators, with caveats.

U.S. major-exchange listing — NYSE, NASDAQ — has been gated by Schedule I status. That gate opens, partially, for operators whose business is meaningfully Schedule III. The path isn't fully clear yet; the exchanges and their regulators are working through what compliance looks like for registered medical operators.

Mixed operators with recreational exposure face the harder path. The Schedule I residual on the recreational side creates ongoing listing complications that medical-only operators won't face.

Canadian-listed U.S. MSOs are evaluating uplisting to U.S. major exchanges. The decision is entity-by-entity and depends on operating mix, regulatory posture, and timing relative to broader regulatory clarity.

For private capital — non-public raises — the environment is improving across the board. More institutional capital, better terms, less regulatory friction.

Cannabis-sector insurance markets have been thin and expensive — small numbers of carriers, high pricing, narrow coverage. Early signals suggest meaningful softening for registered medical operators.

Expect improvement across the main lines: general liability, product liability, property, and directors-and-officers (D&O) for operators with institutional ownership.

The timeline for pricing to normalize is 6 to 18 months. The insurers that lead the cannabis market need time to gather loss experience under the new regime, update their underwriting frameworks, and adjust pricing. Operators should expect modest improvement in 2026 with more substantial improvement in 2027 renewals.

Yes, in several ways.

Forward cash flow. 280E savings starting in tax year 2026 improve EBITDA-to-cash conversion immediately. That changes the look of the business to lenders and investors who price on cash-flow metrics.

Deferred tax assets. Under 280E, future deductions were largely presumed disallowed. With deductions presumed allowable going forward, deferred tax asset positions shift. Your auditors will need to revalue these positions for 2026.

Retroactive refunds. If Treasury eventually issues retroactive 280E relief (still speculative as of May 2026 — see the 280E section), refund-anticipation financing becomes viable for prior tax years. Some specialty lenders are positioning for this market already; it isn't available yet.

Lender treatment. Lenders that price on EBITDA or free cash flow will see immediate improvement in your numbers under the new regime. That feeds into both new financings and renewals of existing facilities.

Engage your auditors early. The first reporting period under the new regime will set disclosure norms for the sector.

The main mechanical changes:

Tax expense. Drops materially starting Q2 2026 — effectively from April 28 forward. Quarterly reporting from Q2 2026 onward will reflect substantially different tax expense than prior periods.

Effective tax rate. ETR disclosure should reflect the rescheduling. Prior-period comparability requires narrative disclosure explaining why the rates moved.

Deferred tax assets and liabilities. Revaluation required given that future deductibility is now presumed rather than presumed-disallowed.

Prior-period comparability. Side-by-side reporting needs narrative context. Investors and lenders looking at multi-year trends need to understand that the comparison points are not on the same regulatory basis.

Retroactive relief. If and when it lands, will trigger additional restatement work for prior years.

This is auditor and CPA territory. Get them engaged on the Q2 2026 close, not the year-end close.

It's the administrative hearing on broader cannabis rescheduling — specifically, whether Schedule III status should extend beyond state-licensed medical and FDA-approved drug products to cover recreational and other currently-Schedule-I cannabis activity.

This is the proceeding that picks up where the Biden-era process collapsed in 2025. It runs through the standard DEA administrative pathway, not the treaty-route shortcut the April 23 order used. That means a full hearing record, expert testimony, public participation by designated parties, scientific evidence review — the long version of the process.

For OMMA-licensed medical operators, the hearing doesn't change anything in the current operating environment. Medical-side rescheduling already happened. The hearing is about whether to extend Schedule III to recreational cannabis, which Oklahoma doesn't have.

The hearing produces a record and a recommendation. It doesn't produce a final rule by itself.

What happens inside: scientific evidence on abuse potential and medical use, public-health considerations, regulatory experience under state programs, the eight-factor analysis. Designated participants — trade associations, advocacy groups, public-health organizations, state regulators — present testimony and evidence. The presiding administrative law judge produces a recommended decision based on the record.

What happens outside: the DEA Administrator decides whether to act on the recommendation. If she does, a proposed rule goes out for public comment. After comments are reviewed, a final rule is issued. Then any litigation challenges to that final rule begin.

The hearing is the first step in a multi-step process. The first step takes months. The full process takes years.

Years, not months. Here's the rough sequence:

• Hearing proceedings: June 29 to no later than July 15, 2026 (DEA's stated conclusion target)
• ALJ recommendation: 2 to 4 months after hearing closes
• Administrator decision on whether to publish a proposed rule: 1 to 3 months
• Notice-and-comment rulemaking: 6 to 12 months minimum
• Litigation against any final rule: separate 12-to-24-month track

Realistic earliest date for a final rule extending Schedule III to recreational: late 2027. More likely 2028. A change of administration in January 2029 could reset everything.

For OMMA-licensed operators, this means recreational rescheduling is not a near-term planning consideration. The medical-side regime you're operating under now is the operative one for the rest of 2026 and most of 2027 regardless of how the June 29 hearing goes.

Section 591 of the draft FY2027 Commerce-Justice-Science appropriations bill would prohibit the DEA from spending appropriated funds to advance cannabis rescheduling beyond the medical-side rule that's already in effect.

If the rider survives conference negotiations and is signed into law, it freezes the DEA's ability to spend on the June 29 hearing and downstream rulemaking — without changing the underlying legal authority to do the work. There are workarounds (internal reallocation, ALJ time as non-DEA staff time, hearing record at minimal marginal cost), but they slow the proceeding.

What the rider does not do: change anything about the existing medical-side rule, the Section 1301.13(k) registration pathway, or 280E relief. Those are settled. The rider is forward-looking — it would slow the broader rescheduling without touching what's already in force.

Watch the FY2027 conference timeline. A signed rider would push the broader rescheduling timeline outward by quarters.

The principal challenger is Smart Approaches to Marijuana (SAM), the most established prohibition-aligned advocacy organization with the capacity to mount sustained federal litigation. SAM has retained former Attorney General Bill Barr to lead its litigation strategy.

Likely co-plaintiffs include other drug-policy reform skeptics, some addiction-medicine professional associations, and possibly state attorneys general from states that opposed rescheduling.

The grounds:

• The treaty-route pathway under Section 811(d)(1) wasn't designed for downscheduling and using it that way exceeds the Attorney General's authority.
• Bypassing notice-and-comment rulemaking violates the Administrative Procedure Act.
• The administrative record is inadequate to support the substantive decision.
• HHS's scientific and medical evaluation, where required, wasn't performed.

This isn't a fringe lawsuit. The Barr involvement adds credibility, federal-litigation depth, and political complexity. Whether the merits succeed is a separate question — but the suit will be taken seriously.

Low for the order as a whole. Higher for specific implementation aspects.

For a court to block the entire order, the challengers would need to show both substantial likelihood of success on the merits and irreparable harm. Both are high bars given that courts give agencies meaningful deference when interpreting ambiguous statutes. Section 811(d)(1) is the kind of provision where reasonable agency interpretation gets weight.

Targeted injunctions against specific implementation pieces — particular registrations, particular FDA-jurisdiction questions, specific banking-treatment provisions — are more plausible if specific procedural defects are identified.

The base case is the order survives. Possibly with some modifications around the edges. Operators planning around the order should plan for it being in force; they should not bet against it.

This is the genuine downside-scenario question, and it deserves a direct answer.

Three plausible paths if a court overturns the order:

Prospective-only reversal. The order is overturned but the court doesn't disturb registrations or tax positions taken in good-faith reliance during the period the order was in effect. Operators absorb a return to Schedule I status going forward but don't face retroactive liability for what they did under the rule. This is the most likely reversal outcome.

Retroactive reversal. The court overturns the order and treats it as void from the beginning. Registrations void. 280E deductions disallowed. Significant practical disruption, though good-faith reliance defenses would generally be available. Lower probability.

Stay pending appeal. A court issues injunctive relief but stays its own order pending appeal, leaving the rule in effect during the appellate process. Operators continue under the rule with awareness of the litigation overhang. Procedurally common regardless of underlying merits.

The asymmetric calculation: the upside of registering (federal cover, banking access, 280E relief, federal commerce relationships) is large and current. The downside in a reversal scenario is real but manageable, and most reversal scenarios protect good-faith reliance. The base case is the order survives. Don't bet against it; do understand the downside.

Four scenarios worth holding in mind, with rough probability ranking for planning purposes:

Full survival (highest probability). The order stands without material modification. Medical-side rule operates as written. The June 29 hearing produces an eventual broader rule on the standard timeline. Banking and capital access progressively improve. This is the base case.

Narrow injunction or modification. Specific implementation aspects are modified by court order or further DEA action; the underlying scheduling change persists. Most likely modification targets: mixed-operator treatment, specific FDA-jurisdiction issues, or particular registration provisions. The medical-side core of the order survives.

Full overturn. The order is vacated on procedural or substantive grounds. Reverts cannabis to pre-April 23 federal status. Significant transitional disruption for operators who registered and reorganized. Lower probability than full survival but not negligible.

Congressional intervention. Congress acts to either codify the rescheduling (the most favorable outcome for the sector — converts agency rule into statutory law and eliminates litigation risk), preempt or override the order, or modify specific implementation through SAFE Banking or related legislation. Moderate probability over the 2026 to 2028 horizon.

These scenarios aren't mutually exclusive. A narrow injunction followed by congressional codification is a plausible composite outcome.

Mixed. Some structural protection, some real exposure.

Final rules survive administration change without affirmative repeal. A future administration can't simply rescind a final rule by executive fiat. Reversing the medical-side rescheduling would require either a new rulemaking to undo it (subject to its own procedural requirements and litigation exposure), congressional action, or a judicial decision invalidating it. None of those are fast.

That said, an administration disposed against the rule in 2029 has options. New rulemaking takes years but is feasible. Enforcement posture can shift overnight. Banking and capital-markets regulators can change examiner instructions.

The most durable insurance against future administrations would be congressional action codifying the rescheduling. That would convert the agency rule into a statute, which is materially harder to unwind. Whether Congress acts on this is the open political question of 2026 through 2028.

For operators making decisions today, the structural durability is real. The discretionary durability — how a future administration chooses to administer the rule — is less certain.